olivLaw · European equity research
Ísfélag hf. ISF.IC
Iceland · Nasdaq Iceland · ISIN IS0000030112 · Vertical: Listed companies from Iceland
At the close of 06 Nov 2026, Ísfélag hf. (ISF.IC) stock was 150.00 ISK (+0.00% on the day), with beta 0.09, 52-week range 118.00–173.00 ISK.
Data as of · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 40.8
- weak (30–45)
- Bollinger (20, 2)
- 144.41 – 158.79
- in the lower half of the band · %B 0.39 · band width 9.5%
- SMA 50 / 200
- 158.51 / 150.18
- mixed trend
- MACD (12, 26, 9)
- -1.91 / -1.87
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | −6.3% | −0.2% | −6.1 pp | — |
| 3 months | −6.8% | −5.4% | −1.4 pp | — |
| 6 months | −0.7% | +4.4% | −5.0 pp | — |
| Year to date | +11.1% | +6.5% | +4.7 pp | — |
| 1 year | +23.0% | +10.0% | +13.0 pp | −7.8% |
| 3 years | unavailable | +48.6% | unavailable | +14.4% |
| 5 years | unavailable | +41.4% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
the price (USD) and the reports are in different currencies
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable |
| Net income | 38.6 m | 16.1 m | 21.5 m |
| Net income YoY | unavailable | −58.3% | +33.7% |
| Diluted EPS | 0.06 | 0.02 | 0.03 |
| Diluted EPS YoY | unavailable | −65.5% | +30.0% |
| net % | unavailable | unavailable | unavailable |
| Free cash flow | 4.8 m | 18.9 m | -10.0 m |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 36.2 m USD
- Financial debt
- 189.7 m USD
- Net debt
- 153.4 m USD
- Equity
- 567.0 m USD
- Total assets
- 865.8 m USD
- Debt / equity
- 0.33x
- Current ratio
- 3.75x
- ROE
- 3.9%
- ROA
- 2.6%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cost of revenue | 125.1 m | 129.6 m | 147.7 m | esef· 07 Apr 2026verified |
| Gross profit | 68.9 m | 41.5 m | 65.9 m | esef· 07 Apr 2026verified |
| Operating income | 57.2 m | 32.3 m | 61.4 m | esef· 07 Apr 2026verified |
| Interest expense | 13.1 m | 10.5 m | 17.5 m | esef· 07 Apr 2026verified |
| Pre-tax income | 48.4 m | 21.7 m | 29.3 m | esef· 07 Apr 2026verified |
| Income tax | 9.7 m | 5.6 m | 7.7 m | esef· 07 Apr 2026verified |
| Net income | 38.6 m | 16.1 m | 21.5 m | esef· 07 Apr 2026verified |
| Diluted EPS | 0.06 | 0.02 | 0.03 | esef· 07 Apr 2026verified |
| Dividend per share | 0.02 | 0.02 | 0.02 | esef· 07 Apr 2026derived |
Balance sheet · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 44.1 m | 36.1 m | 36.2 m | esef· 07 Apr 2026verified |
| Receivables | 30.5 m | 18.4 m | — | esef· 15 Apr 2025verified |
| Inventories | 61.3 m | 38.4 m | 44.9 m | esef· 07 Apr 2026verified |
| Current assets | 141.0 m | 95.1 m | 153.2 m | esef· 07 Apr 2026verified |
| Property, plant & equipment, net | 142.7 m | 168.5 m | 195.6 m | esef· 07 Apr 2026verified |
| Total assets | 804.4 m | 778.1 m | 865.8 m | esef· 07 Apr 2026verified |
| Accounts payable | 17.0 m | 18.2 m | 24.8 m | esef· 07 Apr 2026verified |
| Short-term debt | 17.9 m | 14.8 m | 7.1 m | esef· 07 Apr 2026verified |
| Long-term debt | 124.7 m | 112.1 m | 182.5 m | esef· 07 Apr 2026verified |
| Current liabilities | 48.9 m | 38.7 m | 40.8 m | esef· 07 Apr 2026verified |
| Total liabilities | 250.2 m | 227.3 m | 298.8 m | esef· 07 Apr 2026verified |
| Equity | 554.2 m | 550.7 m | 567.0 m | esef· 07 Apr 2026verified |
| Shares outstanding at year end | 666.4 m | 805.9 m | 828.6 m | esef· 07 Apr 2026derived |
Cash flow · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | 22.5 m | 60.7 m | 46.1 m | esef· 07 Apr 2026verified |
| Capex | 17.7 m | 41.9 m | 56.1 m | esef· 07 Apr 2026verified |
| Free cash flow | 4.8 m ≈ | 18.9 m ≈ | -10.0 m ≈ | esef· 07 Apr 2026derived |
| Investing cash flow | -93.5 m | -40.3 m | -75.5 m | esef· 07 Apr 2026verified |
| Financing cash flow | 87.9 m | -27.3 m | 23.9 m | esef· 07 Apr 2026verified |
| Dividends paid | 15.0 m | 14.8 m | 16.5 m | esef· 07 Apr 2026verified |
| Share repurchases | — | 350.6 k | 0 | esef· 07 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 27.1% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
06 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Price and reporting are in different currencies; market indicators are unavailable.
Key indicators
Coverage and freshness
Score by group
27% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 0.26 – 0.53 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/E0.45 – 0.53 (Mid 0.45)5 companies used · median multiple 17.4x · quartiles 17.2x – 20.2xASAR.IC, BERA.IC, FESTI.IC, HAGA.IC, NOVA.IC
- Dividend discount (DDM)0.26 – 0.35 (Mid 0.30)
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 6.6% | 25 (vs peers) | 38% |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | -46.4% | 0 (on a fixed band) | 23% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 3.5x | 31 (on a fixed band) | 23% |
| Current ratio · Balance sheet | 3.8x | 100 (on a fixed band) | 15% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet59/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality16/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Ísfélag hf. (ISF.IC). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: ROE 3.9%.
The estimated value range is 0.36–0.44 USD per share (median of 2 methods, agreement: high); assumptions are illustrative. The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 3.8x
What contradicts it
- ROIC: 6.6%
- FCF conversion: -46.4%
Not assessed (insufficient data or a ratio without meaning): Net margin, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Listed companies from Iceland · same country · compared with 11 companies
Multiples and returns vs the median
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| HAGA.ICHagar hf. | 131.4 bn | 20.2 | 18.2% | 3.8% | +9.3% | +6% / +80% |
| FESTI.ICFesti hf. | 90.9 bn | 22.8 | 10.1% | 2.6% | +13.4% | −8% / +67% |
| HEIMAR.ICHeimar hf. | 61.3 bn | 7.5 | 13.5% | 55.5% | +7.7% | −6% / +49% |
| BERA.ICÖlgerðin Egill Skallagríms hf. | 37.4 bn | 17.4 | 13.7% | 5.9% | +7.7% | −23% / +1% |
| NOVA.ICNova Klúbburinn hf | 12.0 bn | 14.8 | 8.5% | 6.1% | +2.8% | −26% / −16% |
| ALVO.ICAlvotech | — | — | — | 9.0% | +43.4% | −10% / −57% |
| ASAR.ICSíminn hf. | — | 17.2 | — | — | +3.0% | −20% / +26% |
| BRIM.ICBrim hf. | — | — | 11.9% | 14.6% | +5.2% | +20% / +14% |
| EIK.ICEik Fasteignafélag Hf. | — | — | 10.2% | 43.6% | +9.5% | +1% / +23% |
| EIM.ICEimskipafélag Íslands hf. | — | — | 3.2% | 1.2% | −4.7% | +7% / −35% |
| HAMP.ICHampiðjan hf | — | — | 1.7% | 1.2% | +15.7% | −26% / −36% |
1- and 3-year price returns: for ISF.IC from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202507 Apr 2026
- Annual report 202415 Apr 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.